Skip to main content
An official website of the United States government
Government Funding Lapse
Because of a lapse in government funding, the information on this website may not be up to date, transactions submitted via the website may not be processed, and the agency may not be able to respond to inquiries until appropriations are enacted.

The NIH Clinical Center (the research hospital of NIH) is open. For more details about its operating status, please visit cc.nih.gov.

Updates regarding government operating status and resumption of normal operations can be found at opm.gov.

Email

Vorasidenib Citrate

Placeholder slot
 (vor-uh-SIH-deh-nib SIH-trayt)

Vorasidenib citrate works by entering the brain and blocking the activity of abnormal IDH1 and IDH2 enzymes produced by IDH1 and IDH2 genes with certain mutations. By blocking these enzymes, vorasidenib citrate helps slow or stop the growth of certain types of brain tumors. It is a small-molecule drug (a drug that can enter cells easily).

US Brand Name(s)
Voranigo
FDA Approved
Yes

FDA label information for this drug is available at DailyMed.

Use in Cancer

Vorasidenib citrate is approved to treat:

  • astrocytoma or oligodendroglioma in adults and children aged 12 years and older that is grade 2, has an abnormal IDH1 or IDH2 gene, and has been treated with surgery, including biopsy, to partially or completely remove the tumor.

Vorasidenib citrate is also being studied in the treatment of other types of cancer.

More About Vorasidenib Citrate

Definition from the NCI Drug Dictionary - Detailed scientific definition and other names for this drug.

Research Results and Related Resources

Engaging People with Low-Grade Glioma in Cancer Research

Vorasidenib Treatment Shows Promise for Some Low-Grade Gliomas

Targeted Therapy to Treat Cancer

Clinical Trials Accepting Patients

Find Clinical Trials for Vorasidenib Citrate - Check for trials from NCI's list of cancer clinical trials now accepting patients.

  • Posted:
  • Updated:
Email